BioSpace News Archive

Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced it will present data from three in vitro dissolution studies exploring the dissolution performance of INGREZZA® (valbenazine) capsule contents through soft foods or a gastrostomy (G-tube) feeding tube.

DURECT Corporation announced that Dr. James Brown, President and CEO and additional members of the management team will participate in a fireside chat hosted by Francois Brisebois, Managing Director, Senior Biotechnology Research Analyst at Oppenheimer & Co. Inc. at the Oppenheimer 33rd Annual Healthcare Conference on Wednesday, March 15th, 2023.

InVivo Therapeutics Holdings Corp. (Nasdaq: NVIV) today announced topline results from the company’s INSPIRE 2.0 study, which was designed to evaluate the safety and probable benefit of InVivo’s investigational Neuro-Spinal Scaffold™, a bioresorbable scaffold-based device in development for patients with acute SCI.

Aspen Laser Systems, LLC, an emerging global leader in the medical device industry - with a focus on photobiomodulation, announced the launch of a new Laser Safety Officer and Laser Technician program.

NeuroOne Medical Technologies Corporation today announced its participation in the 35th Annual Roth Conference being held March 12-14, 2023.

CNS Pharmaceuticals, Inc. today announced that the first patient in Switzerland has been enrolled in the Company’s ongoing potentially pivotal global trial evaluating Berubicin for the treatment of recurrent glioblastoma multiforme (GBM), an aggressive and incurable form of brain cancer.

LivaNova PLC, a market-leading medical technology and innovation company, announced Damien McDonald, Chief Executive Officer, will present in a fireside chat at the Barclays Global Healthcare Conference in Miami, Florida.

Marvel Biosciences Corp. (TSXV: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the “Company” or “Marvel”), is pleased to announce that it has initiated the 4-week good laboratory practice (GLP) FDA investigational new drug (IND) enabling dose-ranging rat studies for its lead drug candidate MB-204.

SCA Pharma, a nationally recognized leader in the 503B compounding pharmaceuticals outsourcing industry providing quality, service, and value to hospitals nationwide, has announced the addition of Hugh O’Neill as Chief Commercial Officer.